Alexandria Real Estate Equities Inc vs Sanofi SA — how do they compare? Alexandria Real Estate Equities Inc trades at $48.06 (market cap $8.28B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 12.6× Alexandria Real Estate Equities Inc's market cap, and Alexandria Real Estate Equities Inc pays the higher dividend (5.99%). Which is the better fit depends on your goals.
| ARE | SNY | |
|---|---|---|
Market Cap | $8.28B | $104.30B |
Sector | Real Estate | Health |
52-Week High | $87.45 | $52.34 |
52-Week Low | $40.41 | $41.33 |
Enterprise Value | $20.98B | $124.19B |
Dividend Yield | 5.99% | 5.55% |
Signals from Pluang's Aura AI — not financial advice
Alexandria Real Estate Equities (ARE) trades at $48.07, down 0.58% on the day, with a bearish technical signal and mixed earnings. The stock shows negative profitability metrics, including a net income margin of -37.12% and ROE of -6.29%, though it beat FFO estimates in Q2 2026. Recent news highlights leasing momentum and a narrowed full-year FFO guidance range, while a pending lawsuit adds uncertainty.
The outlook remains cautious due to weak earnings and high debt, but the stock trades below book value, offering potential value. Risks include ongoing losses, litigation, and real estate market volatility. Analyst consensus is mixed with a $53.71 price target, suggesting modest upside if operational improvements materialize.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Trailing returns across standard periods
Latest headlines on both assets
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →